Stock Market Live Friday 18/12 – CURO Share Price Surges Over 125%

latest updates

• Latest 21:05: US Equities Close Lower
• 20:25: US Stock Performance
• 17:10: Myovant Sciences Shares Surge
• 16:35: European Equities Close Lower
• 16:04: CURO Group Stock Surges
• 15:02: Mereo BioPharma, Ultragenyx Team-Up
• 14:33: US Equities Positive
• 14:22: Palantir Technologies
• 14:19: Mesoblast Stock Falls
• 10:45: UK Stock Gainers
• 09:31: Synairgen Shares Surge
• 08:05: European Equities

Latest 21:05
US Equities Close Lower

• DOW: -0.38%
• S&P: -0.19%
• NASDAQ: -0.07%

20:25
US Stock Performance

17:10
Myovant Sciences Shares Surge

$MYOV Myovant Sciences shares are rallied over 8% reaching highs of $26.78 after the company got FDA approval of Orgovyx for the treatment of advanced prostate cancer.

16:35
European Equities Close Lower

• FTSE 100: -0.38%
• DAX: -0.21%
• STOXX 50: -0.44%
• IBEX 35: -1.42%
• CAC 40: -0.39%

16:04
CURO Group Stock Surges

Consumer finance firm, CURO Group’s (NYSE: CURO) share price has skyrocketed after it said on Friday that the company is set to benefit from Katapult’s announced merger with SPAC, FinServ Acquisition Corp (NASDAQ: FSRV)

Full Story: CURO GROUP STOCK SURGES ON NEWS IT WILL BENEFIT FROM KATAPULT AND FINSERV MERGER

CURO: +127.93% $20.03

15:02
Mereo BioPharma, Ultragenyx Team-Up

Mereo BioPharma (NASDAQ: MREO, AIM: MPH) shares are rallying premarket on Friday after the company announced a license and collaboration agreement with Ultragenyx Pharmaceutical (NASDAQ: RARE) for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta (OI).

Full Story: MEREO BIOPHARMA STOCK SURGES ON NEWS OF ULTRAGENYX COLLABORATION

Mereo BioPharma: +47.06% $3.25

14:33
US Equities Positive

• DOW: +0.05%
• S&P: +0.02%
• NASDAQ:  +0.21%

14:22
Palantir Technologies

Palantir Technologies (NYSE: PLTR) shares are trading 3.67% lower at $26.23 after Credit Suisse downgraded the stock from Neutral to Underperform and announced a $17 price target.

14:19
Mesoblast Stock Falls

Biotechnology company Mesoblast (NASDAQ: MESO) shares are plummeting premarket after the company said that its COVID-19 treatment was unlikely to meet its primary endpoint.

Full Story: MESOBLAST STOCK PLUMMETS 31% AFTER TRIAL LOOKS UNLIKELY TO MEET ENDPOINT

10:45
UK Stock Gainers

• Synairgen: +41.65%: SYNAIRGEN SHARES SURGE 25% AFTER SNG001 AWARDED FDA FAST TRACK STATUS
• United Carpets Group: +19.05%: The company is proposing delisting from the AIM as the directors believe that the company is not of a sufficient scale to attract interest from institutional and other investors.
• Mining Minerals & Metals: +15.23%
• AFC Energy: +15.22%: AFC ENERGY SHARES SURGE 18% ON NEWS OF ABB EV CHARGING PARTNERSHIP

 

09:31
Synairgen Shares Surge

Shares of biotechnology company Synairgen (LON: SNG) are rallying on Friday after the company provided an update on its Phase 3 trial evaluating SNG001 as a treatment for Covid-19.

Full Story: SYNAIRGEN SHARES SURGE 25% AFTER SNG001 AWARDED FDA FAST TRACK STATUS

08:05
European Equities

• FTSE 100: -0.04%
• DAX: -0.13%
• STOXX 50: -0.23%
• IBEX 35: -0.40%
• CAC 40: -0.20%

Overnight News:

• Coinbase files confidentially for an IPO
• Coca-Cola will cut about 2,200 jobs globally
• The FDA votes to endorse  Moderna’s coronavirus vaccine

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .